drugset / Trial / NCT04447183

The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.

NCT04447183

Phase 2 Unknown 120 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open, parallel controlled, multi-center clinical trial; 120 subjects were randomly assigned to the test group and the control group according to 3:1.

Timeline

Start
2020-11-23
Primary completion
2024-08
Completion
2024-10

Drugs

EvaluationDrugModalityDoseRoute
Subject rhTSH Protein / enzyme biologic 0.9 mg Intramuscular
Background Radioactive iodine Other / unclassified 1110 mbq Oral